Sara Anne Healy

Sara Anne Healy

Auto-generated profile, based on publicly available information

Sara Anne Healy

Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2023 in Wellcome Open Research
Verified
Journal Article
Open access
MNMalaria G E N
Malaria G E N
MHMuzamil Mahdi Abdel Hamid
Muzamil Mahdi Abdel Hamid
MAMohamed Hassan Abdelraheem
Mohamed Hassan Abdelraheem
DADesmond Omane Acheampong
Desmond Omane Acheampong
AAAmbroise Ahouidi
Ambroise Ahouidi
RPRob W van der Pluijm
Rob W van der Pluijm
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum genome variation data from the MalariaGEN network. It comprises over 20,000 samples from 82 partner studies in 33 countries, including several malaria endemic regions that were previously underrepresented. For the first time we include dried blood spot samples that were sequenced after selective whole genome amplification, necessitating new methods to genotype copy number variations. We identify a large number of newly emerging crt mutations in parts of Southeast Asia, and show examples of heterogeneities in patterns of drug resistance within Africa and within the Indian subcontinent. We describe the profile of variations in the C-terminal of the csp gene and relate this to the sequence used in the RTS,S and R21 malaria vaccines. Pf7 provides high-quality data on genotype calls for 6 million SNPs and short indels, analysis of large deletions that cause failure of rapid diagnostic tests, and systematic characterisation of six major drug resistance loci, all of which can be freely downloaded from the MalariaGEN website.

30 June 2021 in Nature
Verified
Journal Article
Closed access
PDF file
AMAgnes Mwakingwe-Omari
Agnes Mwakingwe-Omari
SHSara A. Healy
Sara A. Healy
JLJacquelyn Lane
Jacquelyn Lane
DCDavid M. Cook
David M. Cook
SKSahand Kalhori
Sahand Kalhori
PDPatrick Emmet Duffy
Patrick Emmet Duffy

1 December 2017 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
IZIrfan Zaidi
Irfan Zaidi
HDHama Diallo
Hama Diallo
SCSolomon Conteh
Solomon Conteh
YRYvette Robbins
Yvette Robbins
JKJacqueline Kolasny
Jacqueline Kolasny
PDPatrick Emmet Duffy
Patrick Emmet Duffy
Whole-sporozoite vaccines confer sterilizing immunity to malaria-naive individuals by unknown mechanisms. In the first PfSPZ Vaccine trial ever in a malaria-endemic population, Vδ2 γδ T cells were significantly elevated and Vγ9/Vδ2 transcripts ranked as the most upregulated in vaccinees who were protected from Plasmodium falciparum infection. In a mouse model, absence of γδ T cells during vaccination impaired protective CD8 T cell responses and ablated sterile protection. γδ T cells were not required for circumsporozoite protein–specific Ab responses, and γδ T cell depletion before infectious challenge did not ablate protection. γδ T cells alone were insufficient to induce protection and required the presence of CD8α+ dendritic cells. In the absence of γδ T cells, CD8α+ dendritic cells did not accumulate in the livers of vaccinated mice. Altogether, our results show that γδ T cells were essential for the induction of sterile immunity during whole-organism vaccination.

1 April 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SHSara A. Healy
Sara A. Healy
CACharles Anderson
Charles Anderson
BSBruce J. Swihart
Bruce J. Swihart
AMAgnes Mwakingwe
Agnes Mwakingwe
EGErin E. Gabriel
Erin E. Gabriel
PDPatrick Emmet Duffy
Patrick Emmet Duffy
BACKGROUND. Vaccines that block human-to-mosquito Plasmodium transmission are needed for malaria eradication, and clinical trials have targeted zygote antigen Pfs25 for decades. We reported that a Pfs25 protein-protein conjugate vaccine formulated in alum adjuvant induced serum functional activity in both US and Malian adults. However, antibody levels declined rapidly, and transmission-reducing activity required 4 vaccine doses. Functional immunogenicity and durability must be improved before advancing transmission-blocking vaccines further in clinical development. We hypothesized that the prefertilization protein Pfs230 alone or in combination with Pfs25 would improve functional activity. METHODS. Transmission-blocking vaccine candidates based on gamete antigen Pfs230 or Pfs25 were conjugated with Exoprotein A, formulated in Alhydrogel, and administered to mice, rhesus macaques, and humans. Antibody levels were measured by ELISA and transmission-reducing activity was assessed by the standard membrane feeding assay. RESULTS. Pfs25-EPA/Alhydrogel and Pfs230D1-EPA/Alhydrogel induced similar serum functional activity in mice, but Pfs230D1-EPA induced significantly greater activity in rhesus monkeys that was enhanced by complement. In US adults, 2 vaccine doses induced complement-dependent activity in 4 of 5 Pfs230D1-EPA/Alhydrogel recipients but no significant activity in 5 Pfs25-EPA recipients, and combination with Pfs25-EPA did not increase activity over Pfs230D1-EPA alone. CONCLUSION. The complement-dependent functional immunogenicity of Pfs230D1-EPA represents a significant improvement over Pfs25-EPA in this comparative study. The rhesus model is more predictive of the functional human immune response to Pfs230D1 than is the mouse model. TRIAL REGISTRATION. ClinicalTrials.gov NCT02334462. FUNDING. Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

11 August 2023 in Expert Review of Vaccines
Verified
Journal Article
Open access
TRThomas L. Richie
Thomas L. Richie
LCL. W. Preston Church
L. W. Preston Church
TMTooba Murshedkar
Tooba Murshedkar
PBPeter F. Billingsley
Peter F. Billingsley
EJEric R. James
Eric R. James
SHStephen L. Hoffman
Stephen L. Hoffman
1. This review is written by the developers of Plasmodium falciparum (Pf) sporozoite (SPZ) vaccines (vaccines comprised of live, metabolically active SPZ) and by researchers who have generated the ...

5 June 2019 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
ASAnnette M. Seilie
Annette M. Seilie
MCMing Chang
Ming Chang
AHAmelia E. Hanron
Amelia E. Hanron
ZBZachary P. Billman
Zachary P. Billman
BSBrad C. Stone
Brad C. Stone
SMSean C Murphy
Sean C Murphy
18S rRNA is a biomarker that provides an alternative to thick blood smears in controlled human malaria infection (CHMI) trials. We reviewed data from CHMI trials at non-endemic sites that used blood smears and Plasmodium 18S rRNA/rDNA biomarker nucleic acid tests (NATs) for time to positivity. We validated a multiplex quantitative reverse transcription–polymerase chain reaction (qRT-PCR) for Plasmodium 18S rRNA, prospectively compared blood smears and qRT-PCR for three trials, and modeled treatment effects at different biomarker-defined parasite densities to assess the impact on infection detection, symptom reduction, and measured intervention efficacy. Literature review demonstrated accelerated NAT-based infection detection compared with blood smears (mean acceleration: 3.2–3.6 days). For prospectively tested trials, the validated Plasmodium 18S rRNA qRT-PCR positivity was earlier (7.6 days; 95% CI: 7.1–8.1 days) than blood smears (11.0 days; 95% CI: 10.3–11.8 days) and significantly preceded the onset of grade 2 malaria-related symptoms (12.2 days; 95% CI: 10.6–13.3 days). Discrepant analysis showed that the risk of a blood smear–positive, biomarker-negative result was negligible. Data modeling predicted that treatment triggered by specific biomarker-defined thresholds can differentiate complete, partial, and non-protective outcomes and eliminate many grade 2 and most grade 3 malaria-related symptoms post-CHMI. Plasmodium 18S rRNA is a sensitive and specific biomarker that can justifiably replace blood smears for infection detection in CHMI trials in non-endemic settings. This study led to biomarker qualification through the U.S. Food and Drug Administration for use in CHMI studies at non-endemic sites, which will facilitate biomarker use for the qualified context of use in drug and vaccine trials.